Skip to Main Content
Aiko Yamada

Aiko Yamada is a counsel in the firm's Tokyo office. She is a member of the firm's corporate mergers and acquisitions, data protection, privacy and security, emerging growth and venture capital, health care and FDA, and technology transactions and sourcing practice groups.

Aiko has over two decades experience in the legal profession. She has represented a broad range of clients with a focus on global pharmaceutical companies, global medical device companies, Japanese and U.S. biotechnology companies, but also including global mobile telecommunications and IT companies and Japanese trading companies.

Aiko was admitted to practice law in Japan in 2000 and in the state of New York, U.S.A. in 2007 and joined the firm in 2020.

Prior to joining the firm, she served as a counsel at a multinational law firm for 20 years, where she gained experience in structuring, negotiating, and implementing various business and finance transactions. She focused her work on mergers and acquisitions, including both domestic and cross-border deals, compliance and corporate governance, and general corporate counseling. She also focused her work on policy and regulatory in the life sciences and healthcare industry and the telecommunications industry, including regulatory and compliance advice on digital health, AI, blockchain, cybersecurity and privacy, IoT and cloud services, internet, e-commerce and social media, telecom services, and software and app development.

From April 2010 to June 2011, she was seconded to a U.S. medical device company as a full-time general counsel. From February 2012 to March 2015, she was seconded to a telecommunications company as a part-time legal counsel.

  • Recognized Practitioner (Life Sciences - Japan) at Chambers Asia-Pacific Awards 2019
  • Noted Practitioner (Life Sciences - Japan) at Chambers Asia-Pacific Awards 2018
  • Research Committee on the Judicial System, Dai-ichi Tokyo Bar Association
  • Legal and regulatory issues in the life sciences and healthcare industry (Financial Management Forums, Inc., December 2016)
  • Legal and business issues on medical big data and gene and cell remedies (Financial Management Forums, Inc., May 2017)
Additional Thought Leadership Pages
  • Co-author, Cross-border M&A Practice (Chuokeizai-sha, Inc., July 2008)
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel